Video

The Changing Landscape of Limited Distribution Specialty Drugs

Michael R. Hess, attorney with Bass Berry & Sims and outside general counsel to many of the largest independent specialty pharmacy companies, discusses developing trends in the limited distribution of specialty medications.

Michael R. Hess, attorney with Bass Berry & Sims and outside general counsel to many of the largest independent specialty pharmacy companies, discusses developing trends in the limited distribution of specialty medications.

Related Videos
Abstract DNA molecule helix inside red blood drop
Woman experiencing pain from UTI -- Image credit: 220 Selfmade studio | stock.adobe.com
Pharmacist helping an older patient -- Image credit: Drazen | stock.adobe.com
Related Content
Eculizumab, Complement inhibitor for rare blood disorder
March 12th 2025

FDA Approves Expanded Indication of Eculizumab for Pediatric Generalized Myasthenia Gravis

Luke Halpern, Assistant Editor
Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education
February 28th 2025

Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education

Luke Halpern, Assistant Editor Jill Simonian, PharmD Codi Peterson, PharmD, MS
FDA logo on a smartphone -- Image credit: gguy | stock.adobe.com
March 10th 2025

FDA Grants Orphan Drug Designation to EN001 for Neuromuscular Disorder, CMT Disease

Gillian McGovern, Associate Editor
Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments
November 25th 2024

Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments

FDA seal of approval -- Image credit: Aquir | stock.adobe.com
March 6th 2025

FDA Approves Expansion for Furosemide Injection to Treat Edema In Patients With CKD

Gillian McGovern, Associate Editor
Structure of the human eye and organization of the retina. Optic part of retina.
March 6th 2025

OpCT-001, Stem Cell-Derived Therapy for Primary Photoreceptor Diseases, Receives FDA Fast Track Designation

Luke Halpern, Assistant Editor